The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
The company's shares fell more than 20 percent Monday on data from the trials of lumateperone, but an analyst wrote that the reason for the high placebo response rate that led to one trial's failure remains unclear.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.